Aarti Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2025
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Drugs has informed the stock exchanges that its 40th Annual General Meeting will be held on Wednesday, September 24, 2025, at 11:00 a.m. via Video Conferencing (VC)/OAVM, and has simultaneously submitted its Annual Report for FY 2024-25. The annual report shows consolidated total revenue of ₹2,403 Crores (down from ₹2,533 Crores in FY24), EBITDA of ₹303 Crores at a 12.6% margin, and Profit After Tax of ₹168 Crores at a 7% margin. Key business highlights include the lifting of the US FDA import alert on the Tarapur API facility, fresh ANVISA and EU-GMP certifications, ₹177 Crores in capex, and a pipeline of 15 oncology products expected to commercialise from FY 2025-26. The company has guided for double-digit revenue growth and 14-15% EBITDA margins in FY 2025-26, supported by capacity ramp-ups at Sayakha and Tarapur, and expansion into regulated markets. Notices and reports are being sent via email to registered shareholders, with e-voting and VC attendance facilities enabled.
Shareholders can review the full-year results and vote electronically at the AGM. The slight revenue dip reflects pricing pressure in APIs, but margin stability, the lifted US FDA alert, and new regulatory approvals point to improved growth visibility going forward.